

**LACK OF CORRELATION BETWEEN ADHERENCE MEASUREMENT METHODS IN NEW-ONSET EPILEPSY**Widyati*¹, Soediatmoko², Dian Maria³, Zullies Ikawati⁴, Lukman Hakim⁴¹Clinical Pharmacist, Dr. Ramelan Navy Hospital, Indonesia²Lecturer at Pharmacy, Faculty of University of Surabaya, Indonesia³Neurologist, Dr. Ramelan Navy Hospital, Indonesia⁴Senior Lecturer at Pharmacy, Faculty of University of Gajah Mada, Indonesia***Corresponding author e-mail:** widyatiw@yahoo.com**ABSTRACT**

Study aims were (1) to document adherence measurement using 3 different methods. (2) to determine the relationship between each methods. The study was conducted using cross sectional design. Patients were followed-up for 6 months and adherences were measured after 1 and 6 months therapy. The methods used to measure the adherences were 1) Patient/parent-self reported (MMAS-8 questionnaires); 2) Drug level assay and 3) seizure frequency observation. Participants enrolled were 50 patients with new-onset general epilepsy ($M_{age} = 7.2 \pm 2.0$; 54 % male; 46% female Indonesian). Patient/parent-self reported methods resulted mean overall adherence scores across patients during this 6-months period was 4.07 ± 1.15 (81.4%). Meanwhile phenytoin assay indicated only 18% patients reached therapeutics concentration. Seizure frequency observation revealed 81% improvement in seizure frequency ($t = 7.63$, $P = 0.000$) after 6 months therapy. Negative correlations were found between Parents/patients-self reporting with drug levels ($\rho = -0.082$, $P = 0.59$); Parents/patients-self reporting with seizure frequency ($\rho = -0.17$, $P = 0.24$). Correlation between seizure frequency with phenytoin level was also proved by Spearman test as no significant ($\rho = 0.12$, $P = 0.42$). 7 patients (14%) remain had seizure after 6 months but only 2 patients were having miss dose. There were lack of correlation between the various methods of adherence measurement but it does not necessarily reflect a minimum in adherence.

Key words: Adherence measurement, Parents/patients-self report, epilepsy**INTRODUCTION**

Patient adherence to Antiepileptic Drug (AED) continues to be a cause of concern within epileptic patients. For individuals with epilepsy, adherence to medication is crucial in preventing or minimizing seizures and their cumulative impact on everyday life. Non-adherence to antiepileptic drugs can result in breakthrough seizures many months or years after a previous episode and can have serious repercussions on an individual's perceived quality of life¹. Stanaway et al² found that 31% of seizures were precipitated by nonadherence to medication. And, as with other chronic medical conditions, estimates

suggest that between 30% and 60% of patients with epilepsy are not adhere with their drug regimens.^{3,4,5}

In assessing the effectiveness of prescribed medication there is a strong emphasis on the ability of the patient to adhere to the regime recommended by the clinician^{6,7}. Various tools have been developed to measure adherence but have limitations. Most research has concentrated on quantifying levels of compliance/adherence without first defining what is meant by both terms⁸. In a review of adherence studies, Vermeire et al⁹ report that adherence has largely been measured using process-orientated definitions involving number of doses missed or taken incorrectly rather than looking at the end result to health. As Farmer¹⁰ in his review of adherence